Among the biggest losers could be Tata Motors, whose subsidiary Jaguar Land Rover (JLR) sells 25 per cent of its products in Europe. Tata Steel Europe and auto parts maker, Motherson Sumi Systems, which sell make-in-UK products in the rest of Europe, may face trade barriers. Indian infotech companies could also lose income, as the British pound fell against the rupee by 7.5 per cent on Friday, which would reduce their export income.
Tata Steel earns almost 57.5 per cent of its revenues from Europe. Just before the vote, both Tata Steel Europe and JLR had cautioned their staff on how the EU is relevant for both companies.
"The EU is by far our largest export market, with over a third of our UK steel heading there... (and) access to that market is fundamental to our business," Tim Morris, head of public affairs at Tata Steel Europe, had said early this month. A Reuters report said the company will take a hit of £1 billion by 2020 due to Brexit.
Shares of TCS, Tata Motors, Tata Steel and Motherson, including other Indian companies with European exposure, fell on the BSE along with Sensex, which ended the volatile Friday with 2.24 per cent fall. Even as Indian companies brace for volatility, chief executive officers (CEOs) said it's business as usual for them. "I think we have seen a knee-jerk reaction today and there is huge job ahead to go out of Europe... As far as I am concerned, it will be business as usual and I do not see any changes, as England is still a part of the EU and does not cease to be because of a referendum," said Vivek Chaand Sehgal, chairman, Motherson Sumi.
CEOs of the information technology sector said the industry was gearing for another phase of uncertainty, as the UK accounted for over 20 per cent exports from India.
One of the worry is if European clients postpone their investment decision, which typically happens in such scenarios.
On the pharma sector, analysts said barring Aurobindo, Brexit will have limited impact on pharma space. While Aurobindo gets 22 per cent of revenue from Europe, Torrent Pharma, Natco and Dr Reddy's get 10-11 per cent of revenues, for others it is lower than five per cent.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)